News
CANF
1.620
+3.18%
0.050
Weekly Report: what happened at CANF last week (0106-0110)?
Weekly Report · 2d ago
CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know
NASDAQ · 5d ago
Weekly Report: what happened at CANF last week (1230-0103)?
Weekly Report · 01/06 09:35
Can-Fite Biopharma Price Target Maintained With a $10.00/Share by D. Boral Capital
Dow Jones · 12/31/2024 15:05
Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital
Dow Jones · 12/31/2024 15:05
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
Benzinga · 12/31/2024 14:54
D. Boral says Can-Fite’s namodenoson may represent liver cancer ‘paradigm shift’
TipRanks · 12/31/2024 13:40
Can-Fite’s Namodenoson to be Highlighted for Liver Protection at ASCO Symposium
TipRanks · 12/30/2024 12:27
Can-Fite BioPharma to Present Data on Namodenoson at 2025 ASCO Gastrointestinal Cancers Symposium
NASDAQ · 12/30/2024 12:11
Can-Fite To Present Data At The 2025 Asco Gastrointestinal Cancers Symposium; Enrolls Patients For Its Pivotal Phase III dvanced Liver Cancer Study
Benzinga · 12/30/2024 12:06
Can-Fite BioPharma announces presentation on namodenoson
TipRanks · 12/30/2024 12:05
Weekly Report: what happened at CANF last week (1223-1227)?
Weekly Report · 12/30/2024 09:33
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
Barchart · 12/30/2024 06:00
Weekly Report: what happened at CANF last week (1216-1220)?
Weekly Report · 12/23/2024 09:35
Weekly Report: what happened at CANF last week (1209-1213)?
Weekly Report · 12/16/2024 09:36
Can-Fite Biopharma Has Received A Notice Of Allowance For A US Patent Titled "AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT (FOR THE TREATMENT OF OBESITY)"
Benzinga · 12/12/2024 20:58
Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now
NASDAQ · 12/09/2024 14:55
Weekly Report: what happened at CANF last week (1202-1206)?
Weekly Report · 12/09/2024 09:35
Biotech Alert: Searches spiking for these stocks today
TipRanks · 12/06/2024 16:20
Can-Fite Biopharma Price Target Maintained With a $10.00/Share by D. Boral Capital
Dow Jones · 12/05/2024 12:16
More
Webull provides a variety of real-time CANF stock news. You can receive the latest news about Can-Fite BioPharma Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About CANF
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.